Figure 2.

Mean change in HbA1c (baseline to endpoint) and relative risk for all-day hypoglycemia in comparative trials of basal analogs vs. NPH insulin plus OADs in T2DM.

Note: definitions of hypoglycemia vary by study; the glargine ‘relative percentages’ have been derived from the study publications and are not comparable to the relative risk data presented for detemir. ^ap < 0.05 for between treatment difference in change in HbA1c between baseline and end of trial, or in risk of hypoglycaemia (De Vries et al 2007 [in press]). © Reproduced with permission.